Key Highlights
- Cash, cash equivalents and marketable securities were USD 117.5 million at September 30, 2026, against an accumulated Deficit of USD 280.7 million.
- The Ceribell System was used by more than 700 hospitals as of September 30, 2026, against about 6,000 United States acute care facilities the company says could benefit.
- FDA clearances arrived in December 2025, June 2026 and September 2026, covering delirium monitoring, two neurology algorithms, next-generation hardware and EEG trend software.
- Management believes cash covers at least the next 12 months and says over 3 million acute care patients a year should be monitored with EEG.
Cash Position Meets a Widening Hospital Footprint
Ceribell (NASDAQ:CBLL) filed its Quarterly Report on November 3, 2026 for the period ended September 30. The medical technology company sells a point-of-care electroencephalogram, or EEG, platform that pairs disposable headbands with a pocket-sized recorder and AI-powered algorithms to detect seizures and delirium in acute care. After about one hour of training, non-specialist staff can apply it within minutes, and neurologists can review data remotely. The supplied filing extract did not include quarterly Revenue or net loss, so this article focuses on cash, adoption and regulatory progress. Cash and marketable securities were USD 117.5 million, and more than 700 hospitals, from top academic centers to small community sites, had adopted the system. Its Clarity product won the first FDA clearance for diagnosing electrographic status epilepticus in May 2023.
Regulatory Clearances and How Revenue Is Earned
The company received FDA 510(k) clearance for its Delirium Monitor System in December 2025, for two neurology algorithms and a next-generation hardware platform in June 2026, and for quantitative EEG trending software in September 2026. Revenue comes from two recurring sources: sales of single-use Wearables, recognized when control transfers, and monthly subscriptions for recorders, software and the portal, recognized over the contract term. Revenue therefore depends on active accounts and Wearable volume, and the filing notes intensive care unit patient numbers are typically lower in summer months, which matters for a third quarter. Territory Managers focus on winning new accounts, while Clinical Account Managers work to raise use in existing hospitals, since clinicians may not use the system on every eligible patient.
Losses, Tariff Exposure and the Funding Question
The company expects continued operating losses as it grows, and says its 12-month cash estimate rests on assumptions that may prove wrong. It may need to raise Capital if cash generated from operations falls short or spending runs higher. Headbands are assembled by contract manufacturers in China and Vietnam, then inspected and labeled in Sunnyvale, California, and cost of revenue includes tariffs and shipping. The company has dual sources for major Wearable components and plans to enlarge its direct sales organization. Its commercial focus is the United States, although it holds a CE Mark in Europe. No peer comparison appeared in the supplied material.
Where Things Stand
On the filing's own estimate, yes for at least 12 months, but the Margin for error is not stated and the company warns it could use cash faster. Ceribell (NASDAQ:CBLL) has USD 117.5 million against an accumulated deficit of USD 280.7 million, more than 700 hospitals and a string of clearances that widen its software offering. Because quarterly revenue and loss figures were not available in the material reviewed, Burn Rate cannot be measured here. Watch the full financial statements, utilization growth in existing hospitals, and any capital raise.






Please wait processing your request...